Fractyl Health (GUTS) Other financing activities (2023 - 2024)
Fractyl Health (GUTS) reported Other financing activities of $2.9 million for Q1 2024, up 1109.32% quarter-over-quarter from $236000.0 in Q4 2023.
Fractyl Health (GUTS) has 2 years of Other financing activities data on file, last reported at $2.9 million in Q1 2024.
- For the quarter ending Q1 2024, Other financing activities changed N/A year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2024 stood at $2.9 million (changed N/A YoY), and the FY2024 full-year result was $2.9 million, up 406.93% from the prior year.
- Other financing activities for Q1 2024 stood at $2.9 million, up from $236000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $2.9 million in Q1 2024 and bottomed at $236000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.85 Mn |
| Mar 31, 2024 | 2.85 Mn |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |